RCKT
Rocket Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.86
+1.85%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 2.1M | 11.0M | — | — | — |
| Gross Profit | (2.1M) | (11.0M) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 124.4M | 142.0M | 171.2M | 186.3M | 165.6M |
| SG&A Expense | 67.5M | 86.5M | 102.0M | 73.3M | 58.8M |
| General & Admin Expense | 67.5M | 86.5M | 102.0M | 73.3M | 58.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (2.4M) | (11.0M) | — | — | — |
| Total Operating Expenses | 189.5M | 217.5M | 273.2M | 259.7M | 224.3M |
| Cost and Expenses | 191.6M | 228.5M | 273.2M | 259.7M | 224.3M |
| Operating Income (EBIT) | (191.6M) | (228.5M) | (273.2M) | (259.7M) | (224.3M) |
| Non-Operating | |||||
| Interest Income | 10.1M | 10.6M | 18.2M | 15.9M | 3.9M |
| Interest Expense | 4.7M | 1.9M | 1.9M | 1.9M | 1.9M |
| Net Interest Income | 5.4M | 8.7M | 16.3M | 14.1M | 2.0M |
| Other Non-Op Income/Expense | 183.0M | 5.4M | 14.5M | 14.1M | 2.5M |
| Non-Operating Income (excl Interest) | (187.7M) | (7.3M) | (16.3M) | (15.9M) | (4.4M) |
| EBT (Pre-Tax Income) | (8.6M) | (223.1M) | (258.7M) | (245.6M) | (221.9M) |
| Income Tax Expense | 8.6M | — | — | — | — |
| Bottom Line | |||||
| Net Income | (17.3M) | (223.1M) | (258.7M) | (245.6M) | (221.9M) |
| Earnings from Cont. Ops | (17.3M) | (223.1M) | (258.7M) | (245.6M) | (221.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (17.3M) | (223.1M) | (258.7M) | (245.6M) | (221.9M) |
| Per Share | |||||
| Basic EPS | ($0.16) | ($2.01) | ($2.73) | ($2.92) | ($3.26) |
| Diluted EPS | ($0.17) | ($2.01) | ($2.73) | ($2.92) | ($3.26) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 112.8M | 111.1M | 94.8M | 84.0M | 68.1M |
| Diluted Shares Outstanding | 114.5M | 111.1M | 94.8M | 84.0M | 68.1M |
| Profitability Metrics | |||||
| EBITDA | 8.0M | (210.2M) | (247.5M) | (236.6M) | (213.7M) |
| D&A | 11.9M | 11.0M | 9.4M | 7.1M | 6.3M |
| EBIT | (3.9M) | (221.2M) | (256.9M) | (243.7M) | (220.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026